Delivering on the promise of Prime Editing
Prime Medicine develops next-generation gene therapies using its proprietary Prime Editing platform, which can search and replace disease-causing genetic sequences without causing double-strand DNA breaks. Founded in 2019 based on technology from the Broad Institute, the company focuses on liver, lung, immunology, and oncology indications. It has a strategic collaboration with Bristol Myers Squibb and is advancing programs toward IND filings.
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingCreate a free account to see funding visualizations and detailed round data.
Create Free AccountJul 2025
Jul 2021
Jul 2021
Create a free account to see which investors have funded this company.
Create Free Account
Late-stage biopharma using single-molecule tracking, AI, and engineering to discover and develop ...
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
South Korean biotech company and global leader in medical aesthetics, manufacturing botulinum tox...
Global full-service clinical research organization (CRO) and scientific advisory partner for biot...
Health insurance company using technology to make health care simple, affordable, and accessible.
Global clinical research organization specializing in early-stage clinical trials and bioanalytic...
